Phase 2 study of ceritinib in ALKi-naive patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM)

被引：9
|
作者：
Felip, E. [1 ]
Orlov, S. [2 ]
Park, K. [3 ]
Yu, C-J. [4 ]
Tsai, C-M. [5 ]
Nishio, M. [6 ]
Dols, M. C. [7 ]
McKeage, M. [8 ]
Su, W-C. [9 ]
Mok, T. S. K. [10 ]
Scagliotti, G. [11 ]
Spigel, D. R. [12 ]
Passos, V. Q. [13 ]
Chen, V. [13 ]
Munarini, F. [14 ]
Shaw, A. [15 ]
机构：
[1] Vall dHebron Univ Hosp, Med Oncol, Inst Oncol, Barcelona, Spain
[2] Pavlov State Med Univ St Petersburg, Thorac Oncol, St Petersburg, Russia
[3] Innovat Canc Med Inst, Hematol Oncol, Seoul, South Korea
[4] Natl Taiwan Univ, Internal Med, Coll Med, Taipei, Taiwan
[5] Taipei Vet Gen Hosp, Thorac Oncol, Taipei, Taiwan
[6] JFCR, Canc Inst Hosp, Thorac Med Oncol, Tokyo, Japan
[7] Hosp Univ Malaga Gen Carlos Haya, Med Oncol, Malaga, Spain
[8] Univ Auckland, Clin Pharmacol, Auckland, New Zealand
[9] Natl Cheng Kung Univ Hosp, Internal Med, Tainan, Taiwan
[10] Chinese Univ Hong Kong, Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[11] Univ Turin, Oncol, Orbassano, Italy
[12] Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA
[13] Novartis Pharmaceut, Oncol, E Hanover, NJ USA
[14] Novartis Pharma AG, Oncol Clin Dev, Basel, Switzerland
[15] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw383.03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1208O
引用
收藏
页数：1
相关论文
共 50 条
  • [21] EVALUATION OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR BRIGATINIB [AP26113] IN PATIENTS (PTS) WITH ALK plus NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES
    Kerstein, D.
    Gettinger, S.
    Gold, K.
    Langer, C. J.
    Shaw, A. T.
    Bazhenova, L. A.
    Salgia, R.
    Dorer, D. J.
    Conlan, M. G.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2015, 26
  • [22] Clinical experience in patients with advanced ALK-Rearranged non-small cell lung cancer and brain metastases in China
    Han, Y.
    Ren, K.
    Zhang, H.
    Sun, L.
    Ren, X.
    ANNALS OF ONCOLOGY, 2018, 29
  • [23] Clinical Efficacy of Alectinib in Patients with ALK-Rearranged Non-small Cell Lung Cancer After Ceritinib Failure
    Oya, Yuko
    Yoshida, Tatsuya
    Kuroda, Hiroaki
    Shimizu, Junichi
    Horio, Yoshitsugu
    Sakao, Yukinori
    Hida, Toyoaki
    Yatabe, Yasushi
    ANTICANCER RESEARCH, 2017, 37 (11) : 6477 - 6480
  • [24] Efficacy of ALK Inhibitors in the Treatment of ALK-rearranged Non-small Cell Lung Cancer and Brain Metastases: A Meta-analysis
    Luo, P.
    Fan, J.
    Zou, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2373 - S2373
  • [25] ALK-Brain Prognostic Index-Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases
    Tsakonas, Georgios
    Kamali, Caroline
    De Petris, Luigi
    Friesland, Signe
    Lewensohn, Rolf
    Ekman, Simon
    CANCERS, 2020, 12 (07) : 1 - 10
  • [26] Resistance mechanisms to lorlatinib or crizotinib in treatment-naive patients (pts) with ALK plus advanced non-small cell lung cancer (NSCLC)
    Felip, E.
    Martini, J-F.
    Mazieres, J.
    Kim, D-W.
    Shepard, D.
    Polli, A.
    Liu, G.
    de Marinis, F.
    Toffalorio, F.
    Goto, Y.
    Solomon, B.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1014 - S1014
  • [27] Resistance mechanisms and efficacy of first-line (1L) alectinib in patients (pts) with ALK-rearranged non-small cell lung cancer (ALK plus NSCLC): Second interim analysis of ALCURE
    Mouri, A.
    Tsuda, T.
    Oki, M.
    Ichihara, E.
    Tanaka, H.
    Azuma, K.
    Arai, R.
    Kuyama, S.
    Akamatsu, H.
    Otsubo, K.
    Ajimizu, H.
    Matsumoto, M.
    Seto, Y.
    Uchibori, K.
    Hayashi, H.
    Miyauchi, E.
    Ishizuka, N.
    Kajihara, Y.
    Nakagawa, Y.
    Katayama, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S1644 - S1645
  • [28] Background of patients (pts) with ALK rearranged (ALK plus ) non-small-cell lung cancer (NSCLC), and efficacy and safety of ALK inhibitors (ALK-Is) in actual clinical practice: Multicenter retrospective study
    Ito, K.
    Saiki, H.
    Sakaguchi, T.
    Hayashi, K.
    Nishii, Y.
    Watanabe, F.
    Hataji, O.
    Okano, T.
    Naito, M.
    Ibata, H.
    Fujiwara, A.
    Yoshida, M.
    Itani, H.
    Tanigawa, M.
    Kobayashi, H.
    ANNALS OF ONCOLOGY, 2015, 26 : 140 - 140
  • [29] Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial
    Ou, Sai-Hong Ignatius
    Tiseo, Marcella
    Camidge, D. Ross
    Ahn, Myung-Ju
    Huber, Rudolf M.
    Hochmair, Maximilian J.
    Kim, Sang-We
    West, Howard Jack
    Reckamp, Karen L.
    Molina, Julian R.
    Liu, Geoffrey
    Delmonte, Angelo
    Ramirez, Santiago Viteri
    Bearz, Alessandra
    Summers, Yvonne J.
    Reichmann, William
    Kerstein, David
    Gettinger, Scott N.
    Kim, Dong-Wan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK plus ) non-small cell lung cancer (NSCLC) in a phase 1/2 trial
    Rosell, R.
    Gettinger, S. N.
    Bazhenova, L. A.
    Langer, C. J.
    Salgia, R.
    Shaw, A. T.
    Narasimhan, N. I.
    Dorer, D. J.
    Kerstein, D.
    Camidge, D. R.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S114 - S114
12345